Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy (FPHAF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
fphaf · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Faron Pharmaceuticals Oy (FPHAF) measures how much investors pay for each dollar of the company's trailing earnings. FPHAF's current PE ratio of N/A is calculated by dividing its stock price of $3.30 by its TTM earnings per share of -$0.07.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2012 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Faron Pharmaceuticals OyYou FPHAF | $210M | N/A | — | -$0.07 |
 Adocia S.A. ADOCY | $170M | N/A | — | -$0.81 |
 Adocia S.A. ADOIF | $104M | N/A | — | -$3.22 |
 AnGes, Inc. AMGXF | $143M | N/A | — | -$14.45 |
 Broncus Holding Corporation BRNHF | $162M | N/A | — | -$0.03 |
 Eupraxia Pharmaceuticals Inc. EPRXF | $108M | N/A | — | -$1.58 |
 Newron Pharmaceuticals S.p.A. NWPHF | $416M | 10.81x | — | $0.85 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-0.00 | — | |
2023-12-31 FY2023 | — | $-0.39 | — | |
2022-12-31 FY2022 | — | $-0.45 | — | |
2021-12-31 FY2021 | — | $-0.35 | — | |
2020-12-31 FY2020 | — | $-0.31 | — | |
2019-12-31 FY2019 | — | $-0.31 | — | |
2018-12-31 FY2018 | — | $-0.54 | — | |
2017-12-31 FY2017 | — | $-0.62 | — | |
2016-12-31 FY2016 | — | $-0.32 | — | |
2015-12-31 FY2015 | — | $-0.25 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Faron Pharmaceuticals Oy (FPHAF) measures how much investors pay for each dollar of the company's trailing earnings. FPHAF's current PE ratio of N/A is calculated by dividing its stock price of $3.30 by its TTM earnings per share of -$0.07.
Frequently asked questions
FPHAF pe ratio · 6 questionsFPHAF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.30 and TTM EPS of -$0.07. Data sourced from Financial Modeling Prep via FPHAF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Faron Pharmaceuticals Oy SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09